FDA-Inspected Site

Barr Laboratories, Inc. (subsidiary of Teva Pharmaceuticals)

16 FDA inspections are on record for Barr Laboratories, Inc. (subsidiary of Teva Pharmaceuticals) in Pomona, United States.

Clean· No action indicated

Pomona, United States · Last updated August 15, 2026

Overview

  • 16 FDA inspections are on record.
  • 4 inspections produced a Form 483.
  • The most recent recorded inspection date is 2017-01-26.

At a glance

Inspections

16

Form 483s

4

EIRs

3

Last outcome

Clean

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
24 Jan 2017 – 26 Jan 2017Human DrugsClean
5 Aug 2015 – 6 Aug 2015Human DrugsClean
7 Jul 2014 – 17 Jul 2014Human Drugs483View 483 →
8 May 2013 – 17 May 2013Human Drugs483View 483 →
3 May 2012Not recordedClean
13 Jan 2012Not recorded483On file
27 Jun 2011Not recordedClean
10 Jun 2010Not recorded483On file
5 Mar 2008Not recordedClean
16 Feb 2007Not recordedClean
14 Jul 2006Not recordedClean
21 Jun 2006Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

17 Jul 2014
21 CFR 211.165(d)

Acceptance/Rejection Levels

Cited by Helen B Ricalde

17 May 2013
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Paul C Mouris

17 May 2013
21 CFR 211.111

Establishment of time limitations

Cited by Paul C Mouris

Investigators

FDA investigators tied to this site in the record.

James A Liubicich3 insp.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.111Cited across public-safe Form 483 observations1x
21 CFR 211.165(d)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind this site's 4 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat